Loading clinical trials...
Loading clinical trials...
A Double Blind, Placebo Controlled, Single and Repeat Dose Escalation Study of GSK2838232 With and Without Ritonavir for 8-11 Days in Healthy Subjects
Conditions
Interventions
GSK2838232
Placebo
+1 more
Locations
1
United States
GSK Investigational Site
Baltimore, Maryland, United States
Start Date
November 18, 2014
Primary Completion Date
June 27, 2015
Completion Date
June 27, 2015
Last Updated
May 9, 2017
NCT06719310
NCT02831673
NCT02075593
NCT01231516
NCT02178592
NCT02415595
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions